Novo Nordisk

Key TakeawaysOzempic's approval may lead to increased prescription rates among type 2 diabetes patients with kidney disease. Competitive positioning as the first GLP-1...

Key Takeaways • Focus on cardiometabolic diseases addresses significant unmet medical needs. • Initial Discovery Awards facilitate reaching crucial pre-clinical milestones. • Expansion incorporates top-tier institutions, enhancing...

Key Insights for Stakeholders - Ascendis stands to receive significant financial incentives contingent upon the success of the collaboration. - The partnership focuses on developing a...

In an era where climate concerns dominate global discourse, renewable energy sources stand at the forefront of sustainable solutions. Among these, solar energy has...

Key TakeawaysNovo Nordisk's Alhemo® (concizumab) has received a positive opinion from the European Medicines Agency (EMA), marking it as the first once-daily subcutaneous...

Key TakeawaysNovo Nordisk's funding supports advanced cell therapy technology development at Evotec. The collaboration aims to produce off-the-shelf cell therapy products for clinical...

Key TakeawaysNanoVation Therapeutics announced a multi-year partnership with Novo Nordisk aimed at developing genetic medicines for cardiometabolic and rare diseases. The collaboration focuses...

Key TakeawaysCovering Wegovy® (semaglutide) for heart disease risk could increase Medicare Part D spending by $34 billion to $145 billion annually. Medicare currently...

key Takeaways:Novo Nordisk announced that the shortage of lower doses of its GLP-1 therapy, Ozempic (semaglutide), is expected to continue into the fourth...

Key Takeaways:Novo Nordisk reported a 24% increase in sales and an 18% rise in operating profit for the first half of 2024, driven...

Novo Nordisk has temporarily halted its pursuit of the Food and Drug Administration (FDA) approval for using its obesity drug Wegovy in treating heart...

Insulin production halt by Novo Nordisk has sparked a campaign by a patient advocacy group to stop the company from discontinuing the insulin product...

Reimbursement for Wegovy, a new obesity medication containing the active substance semaglutide, has been advised against by the Dutch Healthcare Institute. Although Wegovy has...

Insulin icodec a once-weekly basal insulin intended for the treatment of diabetes mellitus, has received a Complete Response Letter (CRL) from the Food and...

Novo Nordisk is bracing for increased competition in the Chinese market, where at least 15 generic versions of its diabetes drug Ozempic and weight...